Compare AbbVie Inc (ABBV) vs Medpace Holdings Inc (MEDP) Price & Performance

AbbVie IncTrade

Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Medpace Holdings Inc — how do they compare? AbbVie Inc trades at $249.78 (market cap $441.94B), while Medpace Holdings Inc trades at $607 (market cap $16.90B). The key difference: AbbVie Inc is far larger — about 26.2× Medpace Holdings Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

	ABBV	MEDP
Market Cap	$441.94B	$16.90B
Sector	Health	Technology
52-Week High	$263.58	$620.59
52-Week Low	$197.38	$393.42
Enterprise Value	$506.19B	$16.52B
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Medpace Holdings Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

MEDP

Medpace Holdings faces lawsuit over alleged misleading growth info causing inflated stock prices.PRNewsWire · 2 days agoBearish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.